- Home
- RDHL vs GLTO Comparison
RDHL vs GLTO Comparison
Compare RDHL & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- GLTO
- Stock Information
- Founded
- RDHL 2009
- GLTO 2011
- Country
- RDHL Israel
- GLTO Denmark
- Employees
- RDHL N/A
- GLTO N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- GLTO Health Care
- Exchange
- RDHL Nasdaq
- GLTO Nasdaq
- Market Cap
- RDHL 6.8M
- GLTO 6.5M
- IPO Year
- RDHL N/A
- GLTO 2020
- Fundamental
- Price
- RDHL $2.60
- GLTO $3.97
- Analyst Decision
- RDHL
- GLTO Buy
- Analyst Count
- RDHL 0
- GLTO 1
- Target Price
- RDHL N/A
- GLTO $10.00
- AVG Volume (30 Days)
- RDHL 177.8K
- GLTO 16.9K
- Earning Date
- RDHL 04-07-2025
- GLTO 04-28-2025
- Dividend Yield
- RDHL N/A
- GLTO N/A
- EPS Growth
- RDHL N/A
- GLTO N/A
- EPS
- RDHL N/A
- GLTO N/A
- Revenue
- RDHL $3,707,000.00
- GLTO N/A
- Revenue This Year
- RDHL $224.90
- GLTO N/A
- Revenue Next Year
- RDHL $82.69
- GLTO N/A
- P/E Ratio
- RDHL N/A
- GLTO N/A
- Revenue Growth
- RDHL N/A
- GLTO N/A
- 52 Week Low
- RDHL $2.57
- GLTO $3.76
- 52 Week High
- RDHL $20.28
- GLTO $21.05
- Technical
- Relative Strength Index (RSI)
- RDHL 15.82
- GLTO 36.86
- Support Level
- RDHL $2.57
- GLTO $3.76
- Resistance Level
- RDHL $3.47
- GLTO $4.21
- Average True Range (ATR)
- RDHL 0.47
- GLTO 0.27
- MACD
- RDHL -0.06
- GLTO -0.01
- Stochastic Oscillator
- RDHL 0.94
- GLTO 22.58
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.